The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Flatiron Health
Stock and Other Ownership Interests - Flatiron Health
Research Funding - Flatiron Health
Travel, Accommodations, Expenses - Flatiron Health
Association between post-treatment (tx) alpha-fetoprotein (AFP) reduction and outcomes in real-world (rw) U.S. patients (pts) with advanced HCC (aHCC).
 
Xiaoliang Wang
Employment - Flatiron Health
Stock and Other Ownership Interests - Flatiron Health
 
Kelly Magee
Employment - Flatiron Health
Stock and Other Ownership Interests - Roche
 
Anala Gossai
Employment - Flatiron Health
Stock and Other Ownership Interests - Flatiron Health
 
Christina M. Parrinello
No Relationships to Disclose
 
Rebecca A. Miksad
Employment - Flatiron Health
Stock and Other Ownership Interests - Flatiron Health; Roche
Consulting or Advisory Role - Grand Rounds (I)
Other Relationship - De Luca Foundation
 
Richard D. Kim
Honoraria - Bristol-Myers Squibb; Lilly
Consulting or Advisory Role - Array BioPharma; Bayer; Bristol-Myers Squibb; Lilly
Speakers' Bureau - Lilly
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene; CytomX Therapeutics (I); Eisai; Flatiron Health; Genoscience Pharma; Gilead Sciences; Gilead Sciences; Incyte; Ipsen; LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; QED Therapeutics; RedHill Biopharma; Roche/Genentech; Silenseed (I); Sillajen; SOBI (I); TheraBionic; twoXAR; Vector Health; Yiviva
Research Funding - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Exelixis (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris